François Liebaert
Plus aucun poste en cours
Profil
François Liebaert served as the Chief Operating Officer & VP-Business Development at BioSystems International SAS.
Prior to that, he was the VP-Medical Affairs, Research & Devel at IntegraGen SA. He holds an MBA from École des Hautes Études Commerciales de Paris and a doctorate from Université de Lille II, which he received in 1985.
Anciens postes connus de François Liebaert
| Sociétés | Poste | Fin |
|---|---|---|
BioSystems International SAS
 BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Directeur des opérations | - |
| INTEGRAGEN | Directeur Technique/Scientifique/R&D | - |
Formation de François Liebaert
| Université de Lille II | Doctorate Degree |
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTEGRAGEN | Health Services |
| Entreprise privées | 1 |
|---|---|
BioSystems International SAS
BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
